We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Owl Rock Capital (ORCC) Offers Notes Worth $450 Million
Read MoreHide Full Article
Owl Rock Capital Corporation recently announced the pricing of its notes, carrying an interest rate of 2.875%. Subject to certain closing conditions, the public offering of worth $450 million notes will mature on Jun 11, 2028.
The net proceeds of the issuance of these notes will be used in clearing debt obligations including the amount under the Revolving Credit Facility due Sep 3, 2025 with respect to $1.295 billion of commitments. The remainder will be used in redeeming all the company’s pending debt that matures on Apr 2, 2024 in relation to its remaining commitments along with the Special Purpose Vehicle (SPV) Asset Facility IV, which matures on Aug 2, 2029.
By capitalizing on the low interest rate environment triggered by the COVID-19 pandemic, the company is attempting to lower its interest burden, thereby aiding margin expansion.
However, its times interest earned stands at 4.4X, way lower than the industry’s average of 37.2X. Its total debt to equity stands at 95.6%, higher than the industry's average of 84.6%. The company’s total liquidity of $2.5 billion is significantly lower than its long-term debt of $5.5 billion. Nevertheless, it takes measures to enhance its financial flexibility without affecting its liquidity position.
Other factors, such as its strong portfolio, growing top line on the back of interest income, inorganic growth initiatives and capital deployment poise this Zacks Rank #3 (Hold) company well for growth.
Shares of Owl Rock Capital have gained 10.9% in the past year against its industry’s decline of 2.6%.
Virtu Financial, Intercorp Financial and XP Inc. managed to deliver a trailing four-quarter surprise of 30%, 257% and 30%, respectively, on average.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Owl Rock Capital (ORCC) Offers Notes Worth $450 Million
Owl Rock Capital Corporation recently announced the pricing of its notes, carrying an interest rate of 2.875%. Subject to certain closing conditions, the public offering of worth $450 million notes will mature on Jun 11, 2028.
The net proceeds of the issuance of these notes will be used in clearing debt obligations including the amount under the Revolving Credit Facility due Sep 3, 2025 with respect to $1.295 billion of commitments. The remainder will be used in redeeming all the company’s pending debt that matures on Apr 2, 2024 in relation to its remaining commitments along with the Special Purpose Vehicle (SPV) Asset Facility IV, which matures on Aug 2, 2029.
By capitalizing on the low interest rate environment triggered by the COVID-19 pandemic, the company is attempting to lower its interest burden, thereby aiding margin expansion.
However, its times interest earned stands at 4.4X, way lower than the industry’s average of 37.2X. Its total debt to equity stands at 95.6%, higher than the industry's average of 84.6%. The company’s total liquidity of $2.5 billion is significantly lower than its long-term debt of $5.5 billion.
Nevertheless, it takes measures to enhance its financial flexibility without affecting its liquidity position.
Other factors, such as its strong portfolio, growing top line on the back of interest income, inorganic growth initiatives and capital deployment poise this Zacks Rank #3 (Hold) company well for growth.
Shares of Owl Rock Capital have gained 10.9% in the past year against its industry’s decline of 2.6%.
Stocks to Consider
Some better-ranked stocks in the same space are Virtu Financial, Inc. (VIRT - Free Report) , Intercorp Financial Services Inc. (IFS - Free Report) and XP Inc. (XP - Free Report) , all presently holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Virtu Financial, Intercorp Financial and XP Inc. managed to deliver a trailing four-quarter surprise of 30%, 257% and 30%, respectively, on average.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>